MDM2 and adrenal cortex carcinoma: For patients with oligometastatic disease, options such as metastasectomy or Stereotactic Body Radiotherapy (SBRT) are available; the ongoing SOLAR phase II trial is investigating the impact of SBRT on disease progression, quality of life, and overall survival in ACC patients with 1 to 5 metastases, with results expected in 2028 [20]Tumor molecular profiling is increasingly important for selecting systemic therapies, as targeted treatments may be effective when specific molecular abnormalities, such as alterations in the MDM2 signaling pathway, are identified [21].